Developing therapeutic antibodies for Alzheimer's disease

开发阿尔茨海默病的治疗抗体

基本信息

批准号：
10821560
负责人：
Miao Sun
金额：
$ 48.96万
依托单位：
VERSAPEUTICS INC
依托单位国家：
美国
项目类别：
财政年份：
2023
资助国家：
美国
起止时间：
2023-09-15 至 2024-08-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/10821560
关键词：
AD transgenic mice Acceleration Adult Affinity Agreement Alzheimer&apos s Disease Alzheimer&apos s disease patient Alzheimer&apos s disease therapeutic American Animal Model Animal Testing Animals Antibodies Binding Biochemical Biological Markers Blocking Antibodies Blood Brain Businesses California Clinical Trials Collaborations Cost of Illness Data Development Disease Progression Dose Drug Kinetics Epitopes Excitatory Synapse Funding Future Genetic Gliosis Glutamates Grant Half-Life Heart Human Impaired cognition In Vitro Individual Infusion procedures Intravenous Bolus Kidney Knock-out Laboratories Late Onset Alzheimer Disease Lead Legal patent Licensing Liver Lung Measures Medical Methods Modeling Morphology Mus Neurons Outcome Pathologic Pathway interactions Penetration Pharmaceutical Preparations Pharmacology Pharmacology Study Phase Production Rattus Regulation Risk Rodent Serum Signal Transduction Small Business Innovation Research Grant Solid Spinal Cord Synapses Testing Tg2576 Therapeutic Therapeutic antibodies Time Tissue Sample Tissues Toxicokinetics United States Universities Variant Wild Type Mouse Work blood-brain barrier penetration caregiving cell bank cognitive function cost cross reactivity density drug candidate drug distribution drug efficacy effective therapy human old age (65+)human tissue humanized antibody immunogenicity in vivo inhibitor interest intravenous administration intravenous injection manufacture mouse model nonhuman primate novel novel strategies novel therapeutic intervention novel therapeutics pharmacologic planar cell polarity pre-clinical preclinical development preclinical study preservation prevent professor receptor scale up stable cell line synaptic function transgenic model of alzheimer disease

项目摘要

PROJECT SUMMARY/ABSTRACT Millions of Americans suffer from Alzheimer’s disease and there are currently no therapies available to prevent or slow the progression of the disease. The unmet medical needs of individuals with Alzheimer’s disease result in hundreds of billions of dollars of costs in paid and unpaid caregiving in the United States every year. VersaPeutics is a small business developing novel therapeutics for Alzheimer’s disease. In this Phase I SBIR project we will perform IND enabling preclinical studies to investigate pharmacokinetics and pharmacology profiles of leading drug product. At the conclusion of these studies, we will have met several important milestones that will support further preclinical development of our novel therapeutics for Alzheimer’s disease.

项目概要/摘要数百万美国人患有阿尔茨海默病，目前尚无治疗方法预防或减缓阿尔茨海默病患者未满足的医疗需求。每年在美国造成数千亿美元的有偿和无偿护理费用。 VersaPeutics 是一家小型企业，在 I 期 SBIR 中开发治疗阿尔茨海默病的小说。我们将进行 IND 项目，进行临床前研究以研究药代动力学和药理学在这些研究结束时，我们将达到几个重要的里程碑。这将支持我们治疗阿尔茨海默病的新疗法的进一步临床前开发。